CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023
23.10.2023 - Cholestatic pruritus expert leads plenary discussion of correlated decreases in serum IL-31 levels and pruritus among patients with PBC treated with seladelpar A second presentation of baseline trial data suggests that any elevation in key liver ... Seite 1 CymaBay Therapeutics, a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, has presented its findings from its Phase 3 ENHANCE study of seladelpar for the treatment of primary biliary cholangitis (PBC). The study found that baseline intensity of patient-reported pruritus was associated with higher serum IL-31 levels in patients with PBC. The results were presented at the American College of Gastroenterology's 2023 International Award. The study also highlighted novel aspects of the anti-pruritic and anti-cholestatic mechanisms of sealadelpar, CymaBay's first-in-class oral, selective PPARδ agonist, being investigated for PBC treatment.
Yayınlanan : 2 yıl önce ile globenewswire içinde
VANCOUVER, British Columbia, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, announced today the presentation of findings from its post-hoc analysis of the Phase 3 ENHANCE study of seladelpar for the treatment of primary biliary cholangitis (PBC), showing baseline intensity of patient-reported pruritus was associated with higher levels of serum IL-31. The presentation, named the recipient of this year’s International Award by the American College of Gastroenterology, will be presented by Professor Andreas E. Kremer, MD, Ph.D., MHBA, a leading authority in cholestatic pruritus from the University of Zurich. Featured results included novel aspects of the anti-pruritic and anti-cholestatic mechanisms of seladelpar, CymaBay’s first-in-class oral, selective PPARδ agonist, or "delpar," being investigated for the treatment of patients with PBC.
The data were previously presented at the European Association for the Study of the Liver (EASL)’s The International Liver Congress 2023 in Vienna, Austria.
“Despite pruritus being an excruciating symptom experienced by many patients with PBC, to date, there has been limited understanding of the underlying pathology of itch and how to effectively treat this issue,” said Dr. Kremer. “These results offer a glimmer of hope in that they link IL-31 levels in patients with PBC to itch. What we are seeing in our research is that treatment with seladelpar is correlated with a significant decrease in both IL-31 levels and levels of patient-reported itch. This is a unique opportunity for researchers to further explore the relationship between the IL-31 pathway and itch, which may help us improve how we address an important, and often distressing, unmet need for patients.”